Lyrus
Lyrus Life Science is a Bangalore-based pharmaceutical CDMO offering end-to-end formulation development, regulatory services and cGMP manufacturing to global pharma clients across nine therapeutic segments and multiple dosage forms.
- Company typePrivate
- Founded2015
- HeadquartersBangalore, India
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Lyrus does
Lyrus Life Science Pvt. Ltd., headquartered in Bangalore, India and founded in 2015, operates as a contract development and manufacturing organisation (CDMO) serving global pharmaceutical companies across regulated and emerging markets. The company offers end-to-end formulation development services spanning pre-formulation, analytical development, pilot and exhibit manufacturing, regulatory dossier preparation (eCTD, ACTD, ANDA) and commercial-scale manufacturing in cGMP-compliant facilities approved by MHRA, EU GMP, FDA, PICs and TGA. Its proprietary technology platforms centre on Novel Drug Delivery Systems (NDDS), nano-technology for bioavailability enhancement of poorly soluble compounds, controlled-release platforms, and innovative primary packaging such as Air-dose packs and Bag on Valve aerosol sprays.
The company's product portfolio comprises 60+ generic and specialty formulations and 150+ registered SKUs across nine therapeutic segments (Neuropsychiatry, Cardiovascular, Diabetes & Endocrinology, Urology, Gastroenterology, Topicals, Pain Management, Anti-Infectives, OTC & Nutraceuticals) in multiple dosage forms including oral solids, oral liquids, topicals and parenterals. Lyrus monetises through multiple revenue streams: contract development and manufacturing fees, out-licensing of dossiers, technology transfer of in-house developed products to local manufacturers in partner markets, sale of its own generic and specialty formulations through distribution arrangements, and dedicated R&D services including stability studies.
Lyrus maintains a commercial presence across Europe, Africa, Australia, MENA, Asia, the USA and Canada, supported by sales/marketing offices in Uxbridge (UK) and Wilmington (USA). The leadership team brings 300+ years of combined pharmaceutical formulation, manufacturing and global marketing experience, with Rajesh Goel serving as Chief Executive Officer. The company is privately held and appears to be founder/management owned, with no disclosed institutional investors or parent company.
Lyrus firmographics
Firmographics- Name
- Lyrus
- Legal name
- Lyrus Life Science Pvt. Ltd.
- Website
- https://lyruslife.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Lyrus Life Science is a Bangalore-based pharmaceutical CDMO offering end-to-end formulation development, regulatory services and cGMP manufacturing to global pharma clients across nine therapeutic segments and multiple dosage forms.
- Ownership category
- akta.pro rank
Lyrus industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Small-Molecule API & Intermediates CDMO (HLAGABAA)
Keywords
Where Lyrus is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices4 records
Markets served
Lyrus business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Contract Development and Manufacturing (CDMO): Contract development and manufacturing of finished formulations for pharmaceutical companies
- Dossier Licensing: Out-licensing of developed dossiers with manufacturing in GMP environment
- Technology Transfer: Technology transfer of products for local manufacturing in partner markets
- R&D Services: Galenical and analytical development, scale-up, pilot batch manufacturing, and stability studies
- Product Sales: Sale of generic and specialty formulations across regulated and emerging markets
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Lyrus product offering
Product offeringCore offering
Lyrus is a B2B contract research, development, and manufacturing organization (CDMO) for the pharmaceutical industry. It provides end-to-end formulation development services covering pre-formulation, analytical development, pilot/exhibit manufacturing, regulatory affairs, and commercial manufacturing. The company also develops and out-licenses its own portfolio of generic and specialty formulations across multiple dosage forms (oral solids, liquids, topicals, parenterals) using proprietary platform technologies including NDDS, nano technology, and bioavailability enhancement.
Product overview
Lyrus is a research and technology-driven global specialty pharmaceutical company offering integrated formulation development and manufacturing services. The core offerings consist of Formulation Development, Pre Formulation, Analytical Development, Pilot and Exhibit Manufacturing, Regulatory Services, and Commercial Manufacturing partnerships. The company maintains a portfolio of 60+ generic and specialty formulations across therapeutic segments including Neuropsychiatry, Cardiovascular, Diabetes & Endocrinology, Urology, Gastroenterology, Topicals, Pain Management, Anti-Infectives, and OTC/Nutraceuticals. Products span multiple dosage forms including oral solids, oral liquids, topicals, and parenterals, developed using advanced platform technologies such as Nano Technology, NDDS, Novel Platform Technologies, and Bioavailability enhancement solutions. Services are offered through contract development, out-licensing of dossiers, and technology transfer arrangements across regulated markets including Europe, Australia, Canada, US, and South Africa.
Differentiator
Problem solved
Functional benefit
Products and services
- Formulation Development End-to-end formulation development services covering NDDS, Novel Platform Technologies, Nano Technology/Bioavailability enhancement, and Nutraceuticals for oral solids, oral liquids, topicals, and parenterals, offered to pharmaceutical companies globally.
- Pre Formulation Comprehensive pre-formulation studies designed to ensure robust dosage forms that can sustain processing and shelf life rigors, minimizing failure rates and development costs for pharmaceutical clients.
- Analytical Development Dedicated analytical services including API characterization, method development, validation, stability testing, release testing, and reference material qualification under cGMP and ICH guidelines, offered to pharmaceutical customers.
- Pilot and Exhibit Manufacturing Integration of development laboratories with industrial manufacturing facilities for pilot batch production, scale-up studies, and validation of manufacturing processes, offered to pharmaceutical clients.
- Regulatory Services Regulatory affairs support including dossier preparation in eCTD, ACTD, ANDA formats, submission procedures (DCP, MRP, National), and regulatory compliance for EMA and FDA markets, offered to pharmaceutical companies.
- Commercial Manufacturing Contract manufacturing partnerships for exhibit and commercial-scale production with facilities approved by MHRA/EU GMP/FDA/PICs/TGA and country-specific authorities, serving pharmaceutical clients globally.
- Generic and Specialty Formulations Portfolio of 60+ products and 150+ SKUs spanning ethical (branded generics), OTC, and nutraceuticals in conventional and novel dosage forms, registered primarily in Africa with expansion into European, Australian, Canadian, US, and South African markets; sold via distribution and licensing partners.
- Contract Research & Development Services Full spectrum CRO services including galenical and analytical development, scale-up, pilot batch manufacturing, stability studies, and technology transfer, offered to pharmaceutical clients along with dossier out-licensing and technology transfer arrangements.
Companies that use Lyrus
Customer profileSegments3 records
Ideal customer profiles2 records
Lyrus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Lyrus partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Lyrus competitors and assessment
Company assessmentDirect peers
- Strides Pharma: India-based specialty generics developer with strong presence in emerging markets and a portfolio of differentiated formulations; comparable to Lyrus on niche generic dossier development and African/regulated market supply.
- Piramal Pharma Solutions: Global CDMO offering formulation development, API and drug product manufacturing across multiple dosage forms with strong regulatory compliance; competes with Lyrus for contract development and dossier licensing work from innovator and generic companies.
- Syngene International: India-headquartered CRO/CDMO providing formulation development, analytical services and contract manufacturing for global pharma, directly comparable to Lyrus on the formulation development and contract manufacturing axis.
- Jubilant Pharmova: India-based integrated CDMO offering solid dosage formulations, parenterals and contract research services to global pharma; overlaps Lyrus on dossier development, scale-up and commercial supply for regulated markets.
Broad incumbents
- Aurobindo Pharma: Major Indian generic and API manufacturer with extensive formulation development, dossier and contract manufacturing capabilities; competes with Lyrus on generic formulation licensing and supply into Africa and other emerging markets.
- Recipharm: European-headquartered CDMO offering formulation development, manufacturing and technology transfer across multiple dosage forms; comparable to Lyrus for European and emerging-market contract engagements.
- Catalent: Global CDMO leader with broad formulation, softgel, biologics and oral drug product capabilities; represents the large incumbent Lyrus competes against for complex formulation and bioavailability-enhancement deals.
- Lonza (Pharma & Biotech): Global CDMO offering drug product and API services including small molecule oral solid dosage forms; competes at the high end of the CDMO market and establishes the scale benchmark Lyrus's customers compare against.
- Dr. Reddy's Laboratories (Custom Pharma Services): Large India-headquartered generics and API player with a substantial contract development services arm covering formulation development and manufacturing across multiple dosage forms; broader portfolio but directly competing for the same CDMO engagements.
Regional players
- Laurus Labs: India-headquartered API and formulation manufacturer with custom synthesis and CDMO services; adjacent peer focused more on APIs but overlaps Lyrus on contract development and emerging-market generic supply.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Lyrus social profiles
Digital presenceLyrus compliance and trust
Trust signalCompliance2 records
Lyrus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lyrus leadership team
Management profileNumber of profiles
Profiles1 record
Lyrus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lyrus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lyrus
What does Lyrus do?
Lyrus is a B2B contract research, development, and manufacturing organization (CDMO) for the pharmaceutical industry. It provides end-to-end formulation development services covering pre-formulation, analytical development, pilot/exhibit manufacturing, regulatory affairs, and commercial manufacturing. The company also develops and out-licenses its own portfolio of generic and specialty formulations across multiple dosage forms (oral solids, liquids, topicals, parenterals) using proprietary platform technologies including NDDS, nano technology, and bioavailability enhancement.
Is Lyrus a public or private company?
Lyrus is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Lyrus founded?
Lyrus was founded in 2015. It employs 101 to 250 people.
Where is Lyrus based?
Lyrus is headquartered in Bangalore, India, in the Asia region.
How does Lyrus make money?
Five revenue lines are on record. Contract Development and Manufacturing (CDMO) is the primary driver. The others are dossier Licensing, technology Transfer, R&D Services and product Sales.
Who are Lyrus's main competitors?
Direct peers on record are Strides Pharma, Piramal Pharma Solutions, Syngene International and Jubilant Pharmova. Broad incumbents are Aurobindo Pharma, Recipharm, Catalent, Lonza (Pharma & Biotech) and Dr. Reddy's Laboratories (Custom Pharma Services). Laurus Labs is listed as a regional player.
Does Lyrus have an API?
No public API is recorded for Lyrus.
What industry is Lyrus in?
Lyrus's product category is Pharmaceutical Contract Development and Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 54171 and its SIC code is 8731.